Theme: Advancements in Research Methods to Eradicate Liver Diseases
Liver Diseases 2023
We cordially welcome you to attend the “14th International Conference on Liver Diseases & Hepatology” which is scheduled during May 22-23, 2023, at Amsterdam, Netherlands.
This year we came up with the refreshing theme “Advancements in Research methods to eradicate liver diseases”. The main objective of the conference is to bring together leading academicians, scientists, researchers, graduate students, (Gastroenterologists,Hepatologists,Pathologists,Oncology) environmental specialist & pharmaceutical specialist and others from all over the world.
Liver Diseases 2023 is a two-day conference organized by Organizing Committee Members where it starts with a keynote session followed by an oral presentation and poster presentations and final ends with the certificate distribution.
Hepatology is the study of Liver, gall bladder, biliary tree and pancreas and its disorders. This is the best chance for all the doctors as well as scientific researchers and students to find out the new techniques in Hepatology and find out the different ways of treatments to be given to the patients affected with Hepatitis. So, don’t miss the opportunity and be a part of it as the new era begins.
With members from around the world focused on learning about Liver Diseases and Hepatology. This is your best opportunity to reach the largest assemblage of participants from the Hepatology community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new developments and research, and receive name recognition at this event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Liver Diseases and Hepatology, treatment and surgery involved are hallmarks of this conference.
About Organization: -
The world's leading expert in organizing academic, scientific, and business conferences, meetings, symposia, and exhibitions in various vertical and horizontal sectors, including medical, pharmacy, engineering, science, technology, and business to advance scientific research. With the kind assistance and collaboration of our 30,000 editorial board members and more than 1,000 scientific societies, we annually host over 3,000 international events, including more than 1,000 conferences, symposia, and workshops throughout the United States, Europe, the Middle East, and Asia. The DOI generated by CROSSREF is included in special issues of our 700+ international open access journals that publish all conference proceedings.
- The sponsoring journals for the conference and the conference book proceedings will both publish all approved abstracts.
- Each abstract will be given a Cross Ref DOI number. Possibility to hold a workshop with your team members
- One-on-one meetings with keynote speakers, OCM, and prominent figures to plan the future course of work.
- The chance to lead a session.
- The organizing committee's certification.
- Specific keynote A page will be made to increase the exposure of your scientific study.
- Massive Discounts for Group Registration, among other things.
Target audience: -
Track 1: Liver Diseases
The liver regulates several essential biological functions. It facilitates toxin elimination, energy storage, and meal digestion. If the body gets sick or hurt, the loss of those skills might do a lot of damage. One of the more than 100 different types of liver disease can affect adults, children, and both sexes. These disorders include non-alcoholic fatty liver disease, cirrhosis, alcoholism, hepatitis A, B, C, D, and E, Epstein-Barr virus (infectious mononucleosis), and iron overload (hemochromatosis). Weakness and fatigue, weight loss, nausea, vomiting, and a yellowing of the skin color are the main symptoms of a liver imbalance (jaundice).
Track 2: Hepatology
- Hepatitis infections.
- Fatty liver disease
- Metabolic liver diseases.
- Liver cancer.
Track 3: Liver Cirrhosis
Cirrhosis, also referred to as liver cirrhosis, hepatic cirrhosis, and end-stage liver disease, is a condition in which the liver's ability to perform its normal functions is compromised by the development of fibrosis, or scar tissue, because of liver disease-related damage. Damage triggers tissue healing and the subsequent formation of scar tissue, which over time can displace normally functional tissue and result in cirrhosis, a condition that impairs the function of the liver.
Symptoms may include tiredness, weakness, loss of appetite, unexplained weight loss, nausea and vomiting, and discomfort in the right upper quadrant of the abdomen. As the disease worsens, symptoms may include itchiness, swelling in the lower legs, fluid build-up in the abdomen, jaundice, bruising easily, and the development of spider-like blood vessels in the skin.
Track 4: Liver Fibrosis
Fibrosis, also known as fibrotic scarring, is a pathological wound healing in which connective tissue replaces normal parenchymal tissue to the extent that it goes unchecked, leading to considerable tissue remodeling and the formation of permanent scar tissue.
When fibroblasts unintentionally produce an excessive amount of extracellular matrix components, like collagen, they can cause fibrosis, which results in a permanent fibrotic scar. This condition is common in people who sustain repeated injuries, chronic inflammation, and need to repair them.
Track 5: Hepatitis
The liver is inflamed by hepatitis. The disorder could be self-limiting, or it might worsen and lead to cirrhosis, liver cancer, or fibrosis (scarring). The most frequent cause of hepatitis in the world is hepatitis viruses, although it can also be brought on by autoimmune illnesses, other infections, and toxic substances (including alcohol and other medications).
There are five different forms of hepatitis viruses: hepatitis A (HAV), hepatitis B (HBV), hepatitis C (HCV), hepatitis D (HDV), and hepatitis E. (HEV). Due to the weight of illness and death they produce as well as the possibility of outbreaks and epidemic spread, these 5 categories are the most concerning. In hundreds of millions of people, types B and C coupled with cancer are the most common causes of chronic illness and liver cirrhosis.
Track 6: Non-Alcoholic Fatty Liver Diseases
The term "non-alcoholic fatty liver disease" (NAFLD) or "metabolic (dysfunction) associated fatty liver disease" (MAFLD) refers to an abnormal accumulation of fat in the liver that has no other obvious cause, such as alcohol consumption. There are 2 types: non-alcoholic steatohepatitis (NASH), which also causes liver inflammation, and non-alcoholic fatty liver (NAFL). Non-alcoholic fatty liver usually does not proceed to NASH and is less harmful than NASH. When NAFL eventually transforms into NASH, it may also bring on side effects like cirrhosis, liver cancer, liver failure, or cardiovascular disease.
Obesity and type 2 diabetes are strong risk factors for NAFLD. Other risks include being overweight, metabolic syndrome (defined as at least three of the five following medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum HDL cholesterol), a diet high in fructose, and older age. NAFLD and alcoholic liver disease are types of fatty liver disease. Obtaining a sample of the liver after excluding other potential causes of fatty liver can confirm the diagnosis.
Track 7: Jaundice
High bilirubin levels cause jaundice, also known as icterus, which is a yellowish or greenish discoloration of the skin and sclera. Adults with jaundice frequently have underlying conditions that involve aberrant heme metabolism, liver malfunction, or biliary-tract obstruction. While jaundice in babies is frequent, with an estimated 80% of cases occurring in the first week of life, it is uncommon in adults. Itching, pale stools, and dark urine are the three symptoms of jaundice that are most frequently seen.
Track 8: Liver Cancer
Cancer that originates in the liver is called liver cancer, often referred to as hepatic cancer, primary hepatic cancer, or primary hepatic malignancy. Liver cancer may manifest as primary (originating in the liver) or secondary (meaning cancer which has spread from elsewhere to the liver, known as liver metastasis). Compared to liver cancer, liver metastasis is more frequent. Globally, there is an increase in liver cancer.
The leading cause of liver cancer is cirrhosis due to hepatitis B, hepatitis C or alcohol. Other causes include aflatoxin, non-alcoholic fatty liver disease and liver flukes.
Track 9:Stem cell treatment on Liver Diseases
An innovative strategy being investigated in this situation is cell therapy. The primary cells of the liver parenchyma, hepatocytes oversee preserving liver health. They can come from one of three places. Hepatocytes can multiply on their own in a healthy liver to rebuild the functional liver mass, a process that may not be working properly in cirrhosis. Second, there are cells in the liver called hepatic progenitor cells that have the capacity to multiply and develop into hepatocytes.
Cirrhosis, which is caused by fibrous septa dividing the liver parenchyma and impairing both liver function (owing to a decrease in functional mass) and normal intrahepatic venous pressure, is a result of chronic liver disorders (due to increased stiffness). While other causes are still difficult to cure, some can be managed with antiviral therapy for hepatitis B or C virus infection, alcohol abstinence for alcohol-related liver disease, or weight loss techniques for metabolic non-alcoholic fatty liver disease (like genetic disorders or autoimmune problems). Some individuals continue to develop end-stage liver disease and its associated consequences, such as ascites, peritonitis, variceal hemorrhage, or hepatocellular cancer, despite current treatments. The only curative option is still liver transplantation because there is no medication available that targets fibrosis and cirrhosis specifically.
- Advanced Cell Therapy
- Differentiation of Hepatocytes
- Biochemistry in Liver Development
- Transplantation of Cell
Track 10: Prevention and Treatment for Hepatitis
Your doctor will first review your medical history to identify any potential risk factors for either infectious or non-infectious hepatitis before diagnosing a patient of hepatitis. The effectiveness of your liver's function can be assessed using blood samples.
A strained, injured, or improperly functioning liver may show high levels of liver enzymes. The organs inside your belly can be visualized via an abdominal ultrasound by using ultrasound waves. It may show the presence of liver tumors, liver dysfunction, or gall bladder abnormalities. Your kind of hepatitis and whether it is acute or will impact your treatment options.
Track 11: Cholestasis
Cholestasis is a condition where bile cannot flow from the liver to the duodenum. The two basic distinctions are an obstructive type of cholestasis where there is a mechanical blockage in the duct system that can occur from a gallstone or malignancy, and metabolic types of cholestasis which are disturbances in bile formation that can occur because of genetic defects or acquired as a side effect of many medications. Classification is further divided into acute or chronic and extrahepatic or intrahepatic.
Track 12: Wilson Disease
Wilson's disease is a hereditary condition in which the body accumulates too much copper. The liver and brain are frequently the sources of symptoms. Vomiting, weakness, fluid retention in the abdomen, swelling of the legs, yellowish skin, and itching are only a few of the symptoms of the liver. Tremors, stiffness in the muscles, difficulty speaking, personality changes, anxiety, and psychosis are a few symptoms associated with the brain.
The Wilson disease protein (ATP7B) gene mutation is the primary cause of Wilson's disease. This protein moves surplus copper into the bile, where it is eliminated in waste materials. Because the disorder is autosomal recessive, a person must inherit a mutant copy of the gene from both parents to be affected. The process of diagnosis, which frequently combines blood, urine, and liver tests, can be challenging.
Wilson's disease is typically treated with dietary changes and medication. Dietary changes involve eating a low-copper diet and not using copper cookware. Medications used include chelating agents such as trientine and d-penicillamine and zinc supplements.
Track 13: Liver transplantation
Liver transplantation or hepatic transplantation is the replacement of a diseased liver with the healthy liver from another person (allograft). Liver transplantation is a treatment option for end-stage liver disease and acute liver failure, although availability of donor organs is a major limitation. The most common technique is orthotopic transplantation, in which the native liver is removed and replaced by the donor organ in the same anatomic position as the original liver. The surgical procedure is complex, requiring careful harvest of the donor organ and meticulous implantation into the recipient. Liver transplantation is highly regulated, and only performed at designated transplant medical centers by highly trained transplant physicians and supporting medical team.
Track 14: Hemochromatosis
Hemochromatosis, also known as iron overload, is the term for the increased overall buildup of iron in the body due to a variety of causes, which can lead to organ damage. The two main contributing factors are trans fusional iron overload, which can happen because of frequent blood transfusions, and hereditary haemochromatosis (HH or HHC), a genetic condition.
Track 15: Gallstones
A gallstone is a stone formed within the gallbladder from precipitated bile components. The term cholelithiasis may refer to the presence of gallstones or to any disease caused by gallstones, and choledocholithiasis refers to the presence of migrated gallstones within bile ducts.
Most people with gallstones (about 80%) are asymptomatic. However, when a gallstone obstructs the bile duct and causes acute cholestasis, a reflexive smooth muscle spasm often occurs, resulting in an intense cramp-like visceral pain in the right upper part of the abdomen known as a biliary colic This happens in 1–4% of those with gallstones each year. Complications from gallstones may include inflammation of the gallbladder (cholecystitis), inflammation of the pancreas (pancreatitis), obstructive jaundice, and infection in bile ducts (cholangitis) Symptoms of these complications may include pain that lasts longer than five hours, fever, yellowish skin, vomiting, dark urine, and pale stools.
Track 16: Acute pancreatitis
- A gallstone impacted in the common bile duct beyond the point where the pancreatic duct joins it
- Heavy alcohol use
- Systemic disease
Acute pancreatitis may be a single event; it may be recurrent; or it may progress to chronic pancreatitis.Mild cases are usually successfully treated with conservative measures: hospitalization, pain control, nothing by mouth, intravenous nutritional support, and intravenous fluid rehydration. Severe cases often require admission to an intensive care unit to monitor and manage complications of the disease. Complications are associated with a high mortality, even with optimal management.
Track 17: Pancreatic cancer
Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass. These cancerous cells can invade other parts of the body. Several types of pancreatic cancer are known.
The most common, pancreatic adenocarcinoma, accounts for about 90% of cases, and the term "pancreatic cancer" is sometimes used to refer only to that type. These adenocarcinomas start within the part of the pancreas that makes digestive enzymes. Several other types of cancer, which collectively represent most of the non-adenocarcinomas, can also arise from these cells. About 1–2% of cases of pancreatic cancer are neuroendocrine tumors, which arise from the hormone-producing cells of the pancreas. These are generally less aggressive than pancreatic adenocarcinoma.
Signs and symptoms of the most-common form of pancreatic cancer may include yellow skin, abdominal or back pain, unexplained weight loss, light-colored stools, dark urine, and loss of appetite.
Liver Diseases Therapeutics Market size was valued at USD 11.55 Billion in 2020 and is projected to reach USD 20.1 Billion by 2028, growing at a CAGR of 11.72% from 2021 to 2028.
Liver disease can be inherited (genetic) or brought on by factors that harm the liver, such as viruses (hepatitis A, B, and C) and alcohol consumption. Obesity has also been linked to liver disease. The liver is necessary for food digestion and for regulating the toxicity of substances in the body. Damage to the liver causes scarring (cirrhosis), which can lead to liver failure, which is a life-threatening condition if not treated. In 2019, approximately 2 million people died from the liver disease worldwide, with 1 million dying from cirrhosis complications and 1 million dying from viral hepatitis and hepatocellular carcinoma. Cirrhosis is the 11th most common cause of death worldwide, and liver cancer is the 16th most common cause of death, accounting for 3.5 percent of alldeaths worldwide.
In addition, chronic liver disease mortality in the United States is expected to rise, owing to an increase in nonalcoholic fatty liver disease (NAFLD). The rising prevalence of liver diseases aided in the market’s expansion. As a result, the rise in liver diseases has aided in the growth of the overall market. Furthermore, with the rising prevalence of liver diseases, governments, and other non-profit organizations are playing an increasingly important role in raising liver disease awareness around the world. As a result, all these organizations are dedicated to raising awareness about liver diseases and providing funding for research and development into the prevention, treatment, and cure of liver diseases
We gratefully express thank all our pleasing speakers, conference attendees, students for making LIVER DISEASES 2022 Conference the best!
The “13th International Conference on Liver Diseases and Hepatology” was held during November 15, 2022, as a Webinar. The generous response was received from the Editorial Board Members of Journals along with scientists, researchers, students, and leaders from various fields of Hepatology, who made this event a grand success. We are acknowledging with gratitude and support by all the Editorial Board Members of emergency medicine Case Reports for their valuable suggestions for the growth of the Organization.
The conference was initiated with the Honorable presence of the Keynote forum. The heartfelt gratitude to the Organizing Committee Associates, many external experts, company representatives and other eminent personalities who supported the conference by facilitating the discussion forums. We also took the privilege to felicitate the Organizing Committee Members, Editorial Board Members and Media Partners who supported this event.
By the outstanding accomplishment of LIVER DISEASES 2023, it is proud to announce the “14th International Conference on Liver Diseases and Hepatology” to be held during May 22-23 2023, at Amsterdam, Nether lands. Liver Diseases 2023 has been organized with the intention and the specific intent of promoting the development of new perspectives and ideas for exploiting the high level of Awareness attained by the scientific community in various Gastroenterology Services.
Let us meet at @ Liver Diseases 2023
To share your views and research, please click here to register for the Conference.